Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18856326 | 1.00 | ABCB1 (0.38) | ABCB1FAAHLMNACA2CNR1 | |
| SCHEMBL22844399 | 0.93 | ABCB1 (0.35) | ABCB1FAAHLMNACA2CNR1 | |
| SCHEMBL20260444 | 0.89 | ABCB1 (0.38) | ABCB1FAAHLMNACA2CNR1 | |
| SCHEMBL18388357 | 0.88 | ABCB1 (0.40) | ABCB1FAAHLMNACA2CNR1 | |
| SCHEMBL18856272 | 0.85 | FAAH (0.37) | ABCB1FAAHLMNACNR1CNR2 | |
| SCHEMBL22844380 | 0.85 | FAAH (0.37) | ABCB1FAAHLMNACNR1CNR2 | |
| SCHEMBL18558912 | 0.85 | FAAH (0.37) | ABCB1FAAHLMNACNR1CNR2 | |
| SCHEMBL20260309 | 0.85 | FAAH (0.37) | ABCB1FAAHLMNACNR1CNR2 | |
| SCHEMBL18558907 | 0.85 | FAAH (0.39) | ABCB1FAAHLMNACA2CNR1 | |
| SCHEMBL20697377 | 0.82 | MMP1 (0.30) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ABCB1 908/4885FAAH 565/4885LMNA 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.